Table S1. Univariate and multivariable analyses of local progression-free survival

	Univariate			Multivariable		
	HR	95% CI	p-value	HR	95% CI	p-value
Age (yr)	0.98	0.93–1.03	0.416			
Sex (male vs. female)	1.84	0.65–5.24	0.252			
ECOG performance status (1 vs. 0)	1.34	0.47–3.81	0.581			
Disease extent (BRPC vs. LAPC)	0.64	0.08–4.81	0.661			
Tumor location (head vs. other)	2.05	0.75–5.56	0.159			
Induction CT duration (mo)	0.83	0.56–1.24	0.368			
Induction CT (FFX vs. GnP)	0.68	0.15–3.04	0.618			
Grade (I/II vs. III)	0.85	0.29–2.48	0.762			
Resected (yes vs. no)	0.51	0.20–1.33	0.167			
CTV (cm^3)	1.01	1.00–1.02	0.019			
Baseline CA19-9 (U/mL)	1.00	0.99–1.00	0.222			
Pre-SBRT CA19-9 (U/mL)	1.00	0.99–1.00	0.984			
Baseline total bilirubin (mg/dL)	1.06	0.91–1.17	0.369			
Pre-SBRT						
ALC (×10^3/μL)	1.21	0.63–2.11	0.542			
NLR	0.90	0.64–1.08	0.438			
Post-SBRT						
ALC (×10^3/μL)	1.02	0.26–3.34	0.975			
NLR	0.96	0.75–1.11	0.665			

ECOG, Eastern Cooperative Oncology Group; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; CT, chemotherapy; FFX, FOLFIRINOX; GnP, gemcitabine/nab-paclitaxel; CTV, Clinical target volume; CA19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; NLR, neutrophil to lymphocyte ratio; HR, hazard ratio; CI, confidence interval.